What is William Blair's Forecast for MDxHealth Q1 Earnings?

MDxHealth SA (NASDAQ:MDXH - Free Report) - Investment analysts at William Blair lifted their Q1 2025 earnings per share (EPS) estimates for MDxHealth in a research report issued on Wednesday, February 26th. William Blair analyst A. Brackmann now anticipates that the company will post earnings per share of ($0.15) for the quarter, up from their prior forecast of ($0.16). The consensus estimate for MDxHealth's current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth's Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.43) EPS and FY2026 earnings at ($0.34) EPS.

Separately, Piper Sandler decreased their price target on MDxHealth from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Thursday, November 7th.

MDxHealth Trading Up 2.6 %

NASDAQ:MDXH traded up $0.04 during mid-day trading on Monday, reaching $1.60. The company's stock had a trading volume of 267,095 shares, compared to its average volume of 86,831. The company's fifty day simple moving average is $1.97 and its two-hundred day simple moving average is $2.16. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45. MDxHealth has a twelve month low of $1.55 and a twelve month high of $3.85. The stock has a market cap of $75.66 million, a P/E ratio of -1.05 and a beta of 1.34.

Remove Ads

MDxHealth (NASDAQ:MDXH - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.07. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. The business had revenue of $24.74 million for the quarter, compared to analyst estimates of $22.67 million.

Institutional Trading of MDxHealth

A number of hedge funds have recently added to or reduced their stakes in the business. AWM Investment Company Inc. raised its holdings in shares of MDxHealth by 11.1% in the 4th quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company's stock worth $11,189,000 after purchasing an additional 471,290 shares during the period. MVM Partners LLC raised its holdings in shares of MDxHealth by 3.3% in the 3rd quarter. MVM Partners LLC now owns 4,700,457 shares of the company's stock worth $9,706,000 after purchasing an additional 150,000 shares during the period. Samjo Management LLC raised its holdings in shares of MDxHealth by 130.9% in the 4th quarter. Samjo Management LLC now owns 1,824,312 shares of the company's stock worth $4,324,000 after purchasing an additional 1,034,312 shares during the period. Perkins Capital Management Inc. raised its holdings in shares of MDxHealth by 31.6% in the 4th quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company's stock worth $2,331,000 after purchasing an additional 236,100 shares during the period. Finally, Northern Trust Corp purchased a new position in shares of MDxHealth in the 4th quarter worth about $1,033,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.